Phase I Trial of LMP2 Antigen-specific TCR T-cell Therapy for Recurrent and Metastatic NPC Patients
NCT03925896
·
clinicaltrials.gov ↗
PHASE1
Phase
UNKNOWN
Status
27
Enrollment
OTHER
Sponsor class
Conditions
Nasopharyngeal Carcinoma
Interventions
DRUG:
LMP2 Antigen-specific TCR T cells
Sponsor
Sun Yat-sen University